Stocks in play: Oncolytics Biotech® Inc.
Announced the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer. Oncolytics Biotech® Inc. shares T.ONC are trading down $0.05 at $1.52.
Read:
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates
Harnessing AI's $4.4 Trillion Potential Reshapes the Tech Industry Landscape
Critical Push for US Domestic Nickel Needed to Halt Total Reliance on Questionable Foreign Imports
How Argentina’s New Power Moves Look to Lure Even More Lithium Interest Towards the Country
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer